Frontlight ResearchEarly access
Amyloidosis trials in Germany
12 of 33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 4Not yet taking people in GermanyA Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
- Where
- Berlin, Bonn, Darmstadt, Greifswald, Hamburg, Ulm
- Age
- 18 years to 90 years
- People
- 50 worldwide
- Run by
- Bayer
See details and how to joinNCT07298044 · EU 2025-521831-35-00 - Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Berlin, Essen, Heidelberg, Munich, Wuerzburg
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - Phase 3Taking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel, München, Munich, Münster, Würzburg
- Age
- 18 years and over
- People
- 1,280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Berlin, Cologne, Dresden, Erlangen, Goettingen, Hanover, Heidelberg, Leipzig, Magdeburg, Muenster, Munich, Wuerzburg
- Age
- 18 years to 85 years
- People
- 1,750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - No phaseTaking peopleEdge-to-edge Mitral Valve Repair in ATTR-CM
- Where
- Hanover, Heidelberg, München
- Age
- 18 years and over
- People
- 106 worldwide
- Run by
- Medical University of Vienna
See details and how to joinNCT06075823 - Phase 3Active, not recruitingTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Berlin, Heidelberg, Muenster
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - Phase 3Not yet taking people in GermanyAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Berlin, Cologne, Essen, Gie En, Hamburg, Hanover, Heidelberg, Homburg, Kiel, Leipzig, M Nchen, Münster, W Rzburg
- People
- 1,180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - Phase 1/2Not yet taking people in GermanyA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Berlin, Essen, Heidelberg, Wuerzburg
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 3Not yet taking people in GermanyTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- Berlin, Heidelberg, Mainz
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Berlin, Heidelberg, Mainz
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - Phase 3Enrolling by invitationAn Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Where
- Cologne, Heidelberg, Homburg, Münster, Würzburg
- Age
- 18 years and over
- People
- 1,400 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493 - Phase 1Taking peopleCLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL)
- Where
- Heidelberg
- Age
- 18 years and over
- People
- 7
- Run by
- Universitaetsklinikum Heidelberg AöR
See details and how to join2025-520790-39-00